Otlertuzumab

A recombinant single-chain polypeptide engineered to exhibit the full binding and activity of an anti-CD37 monoclonal antibody with potential immunostimulatory and antineoplastic activities. Otlertuzumab binds to CD37 on B-cells, which may result in antibody-dependent cell-mediated cytotoxicity (ADCC) and apoptosis. CD37 is a transmembrane glycoprotein expressed at high-levels on B cells and to a lesser extent on T cells and myeloid cells. This agent may have a longer half-life in vivo than conventional monoclonal antibodies. (NCI Thesaurus)

YOU MAY ALSO LIKE

Otitis Media

An acute or chronic inflammatory process affecting the middle ear.

Otitis

Inflammation of the ear, which may be marked by pain, fever, abnormalities of hearing, hearing loss, tinnitus, and vertigo. Inflammation of the…

Otic Suspension Dosage Form

A suspension intended for administration either on the outer ear or into the auditory canal.

Otic Solution Dosage Form

A solution intended for administration either on the outer ear or into the auditory canal.

Otic Ointment Dosage Form

An ointment intended for administration either on the outer ear or into the auditory canal.

Otic Dosage Form

A substance intended for administration either on the outer ear or into the auditory canal.